21 studies found for:    benzamide
Show Display Options
Rank Status Study
1 Completed Benzamide Derivates as Treatment of Clozapine-induced Hypersalivation
Condition: Clozapine-induced Hypersalivation
Intervention: Drug: Amisulpride, Moclobemide
2 Completed Metoclopramide as Treatment of Clozapine-induced Hypersalivation
Condition: Clozapine-induced Hypersalivation
Interventions: Drug: Metoclopramide;   Drug: placebo
3 Completed An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)
Condition: Advanced Solid Tumors
Intervention: Drug: Iniparib
4 Completed Safety and Pharmacokinetics of SAR240550 (BSI-201) Twice Weekly in Patients With Advanced Solid Tumors
Condition: Advance Solid Tumors
Interventions: Drug: Iniparib (SAR240550 - BSI-201);   Drug: Gemcitabine;   Drug: Carboplatin
5 Recruiting Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031 AM4)
Condition: Chemotherapy-Induced Nausea and Vomiting
Interventions: Drug: Fosaprepitant dimeglumine;   Drug: Fosaprepitant Placebo;   Drug: Dexamethasone;   Drug: Ondansetron;   Drug: Dexamethasone Placebo;   Drug: Ondansetron Placebo;   Drug: Rescue Therapy
6 Recruiting A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225 AM1) (KMEC)
Conditions: Nausea;   Vomiting
Interventions: Drug: Aprepitant;   Drug: Aprepitant Placebo;   Drug: Ondansetron;   Drug: Dexamethasone;   Drug: Ondansetron Placebo;   Drug: Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).
7 Completed Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
Condition: Vomiting
Interventions: Drug: aprepitant;   Drug: ondansetron;   Drug: dexamethasone;   Drug: placebo to aprepitant;   Drug: placebo to dexamethasone;   Drug: rescue medication
8 Completed Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Condition: Chromaffin-tissue Derived Tumors
Intervention: Other: Scintigraphy in 123I-IBZM
9 Completed A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia
Conditions: Myelodysplastic Syndrome;   Acute Myelogenous Leukemia
Intervention: Drug: MGCD0103
10 Recruiting Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS
Condition: Myelodysplastic Syndrome
Interventions: Drug: Mocetinostat;   Drug: Azacitidine
11 Completed A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: MGCD0103
12 Completed Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Conditions: Tumors;   Non Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
13 Completed A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
Condition: Tumors
Interventions: Drug: MGCD0103;   Drug: Gemcitabine
14 Completed A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia
Condition: Lymphocytic Leukemia, Chronic
Intervention: Drug: MGCD0103
15 Terminated Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Conditions: Breast Cancer;   Lung Cancer;   Pulmonary Cancer;   Non-Small-Cell Lung Carcinoma;   Prostate Cancer;   Prostatic Cancer;   Gastric Cancer;   Stomach Cancer
Intervention: Drug: MGCD0103 & Docetaxel
16 Terminated Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Condition: Hodgkin's Lymphoma
Intervention: Drug: MGCD0103
17 Terminated MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)
Intervention: Drug: MGCD0103 and Azacitidine
18 Completed Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma
Condition: Lymphoma
Intervention: Drug: MGCD0103
19 Completed A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes
Conditions: Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: MGCD0103
20 Terminated MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Conditions: Myelogenous Leukemia, Acute;   Myelodysplastic Syndromes
Intervention: Drug: MGCD0103

Previous Page Studies Shown (1-20) Next Page (21-21) Show next page of results
Indicates status has not been verified in more than two years